Weinberg Uri's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 3, 2026
- Accession no.
- 0001811030-26-000002
- Filed
- Mar 3, 2026
- Trade date
- Feb 27-Mar 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $146.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weinberg UriCIK 0001811030 | Officer (Chf Medical and Innovation Ofr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Ordinary Shares | SSaleDisposed | −7,461 | $13.84F2 | −$103,260.24 | 213,757 | Direct | |
| Feb 28, 2026 | Ordinary Shares | AGrant or awardAcquired | +12,992 | $0.00 | $0 | 226,749 | Direct | |
| Mar 2, 2026 | Ordinary Shares | SSaleDisposed | −3,272 | $13.33F4 | −$43,615.76 | 223,477 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $13.79 USD to $13.91 USD; the price reported above reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $13.31 USD to $13.36 USD; the price reported above reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.